Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/179214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCantón, Rafael-
dc.contributor.authorLoza, Elena-
dc.contributor.authorArcay, Ricardo M.-
dc.contributor.authorCercenado, Emilia-
dc.contributor.authorCastillo, Francisco Javier-
dc.contributor.authorCisterna, Ramón-
dc.contributor.authorGálvez Benítez, Lidia-
dc.contributor.authorGonzález Romo, Fernando-
dc.contributor.authorHernández Cabezas, Alicia-
dc.contributor.authorRodríguez Lozano, Jesús-
dc.contributor.authorSuárez Barrenechea, Ana Isabel-
dc.contributor.authorTubau, Fe-
dc.contributor.authorDíaz Regañón, Jazmín-
dc.contributor.authorLópez Mendoza, Diego-
dc.contributor.authorSMART-Spain Working Group-
dc.date.accessioned2021-07-19T09:04:42Z-
dc.date.available2021-07-19T09:04:42Z-
dc.date.issued2021-03-01-
dc.identifier.issn0214-3429-
dc.identifier.urihttp://hdl.handle.net/2445/179214-
dc.description.abstractObjective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSociedad Española de Quimioterapia-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.37201/req/019.2021-
dc.relation.ispartofRevista Española de Quimioterapia, 2021, vol. 34, num. 3, p. 228-237-
dc.relation.urihttps://doi.org/10.37201/req/019.2021-
dc.rightscc by-nc (c) Cantón, Rafael et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationPseudomonas-
dc.subject.classificationResistència als medicaments-
dc.subject.classificationMedicaments antibacterians-
dc.subject.classificationEpidemiologia-
dc.subject.otherPseudomonas-
dc.subject.otherDrug resistance-
dc.subject.otherAntibacterial agents-
dc.subject.otherEpidemiology-
dc.titleAntimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-07-16T08:27:00Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33645948-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
canton01mar2021.pdf493.5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons